CytoMed Therapeutics Limited
GDTCNASDAQHealthcare● Active
$1.07
$-0.09(-7.39%)
Market Cap$12601969
P/E Ratio—
52W High$3.68
52W Low$0.68
CytoMed Therapeutics Limited (GDTC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GDTC · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Sep 30, 2025EPS Actual
-$0.07
Revenue
$0.00B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Sep 30, 2025
After Market Close
GDTC reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Nov 13, 2026 | — | — | — | — | — | — |
| ◌ Q4 FY2026 | Nov 13, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 4, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | Apr 27, 2026 | — | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 31, 2026 | — | — | — | — | — | — |
| — Q3 FY2025 | Sep 30, 2025 | — | -$0.07 | — | $0.00B | — | — |
| — Q1 FY2025 | Mar 31, 2025 | — | -$0.05 | — | $0.00B | — | — |
| — Q3 FY2024 | Sep 30, 2024 | — | -$0.04 | — | $0.00B | — | — |
Q4 FY2026
Nov 13, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2026
Nov 13, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 31, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 30, 2025
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025
EPS Actual
-$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Sep 30, 2024
EPS Actual
-$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2025 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2024 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q1 FY2024 | $-0.03 | $-0.03 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Sep 30, 2025 | — | $1.98 | $1.99 | +0.51% |
| — Q1 FY2025 | Mar 31, 2025 | — | $2.25 | $2.18 | -3.11% |
| — Q3 FY2024 | Sep 30, 2024 | — | $1.55 | $1.57 | +1.29% |
| — Q2 FY2024 | Jun 30, 2024 | — | $2.08 | $2.00 | -3.85% |
| — Q2 FY2024 | May 6, 2024 | — | $2.06 | $2.15 | +4.37% |
| — Q1 FY2024 | Mar 31, 2024 | — | $2.17 | $2.24 | +3.23% |
| — Q3 FY2023 | Sep 30, 2023 | — | $3.50 | $3.50 | +0.00% |
Q3 FY2025+0.51%
Report Date
Sep 30, 2025
EPS Beat/Miss
—
Price Before
$1.98
Price After
$1.99
Q1 FY2025-3.11%
Report Date
Mar 31, 2025
EPS Beat/Miss
—
Price Before
$2.25
Price After
$2.18
Q3 FY2024+1.29%
Report Date
Sep 30, 2024
EPS Beat/Miss
—
Price Before
$1.55
Price After
$1.57
Q2 FY2024-3.85%
Report Date
Jun 30, 2024
EPS Beat/Miss
—
Price Before
$2.08
Price After
$2.00
Q2 FY2024+4.37%
Report Date
May 6, 2024
EPS Beat/Miss
—
Price Before
$2.06
Price After
$2.15
Q1 FY2024+3.23%
Report Date
Mar 31, 2024
EPS Beat/Miss
—
Price Before
$2.17
Price After
$2.24
Q3 FY2023+0.00%
Report Date
Sep 30, 2023
EPS Beat/Miss
—
Price Before
$3.50
Price After
$3.50
Beat Rate0 / 7 quarters
Largest Move+4.37% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GDTC ends December
CytoMed Therapeutics Limited (GDTC) most recently reported earnings on September 30, 2025 for Q3 FY2025, posting EPS of $-0.07 (in line with the analyst consensus of —). The next GDTC earnings date is expected around September 1, 2026.
Each quarter, investors track GDTC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GDTC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GDTC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GDTC earnings · 4 questionsCytoMed Therapeutics Limited's next earnings report is expected around September 1, 2026. GDTC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GDTC historically reports after market close (AMC).
GDTC earnings datewhen is GDTC earningsGDTC next earnings datewhen does GDTC report earningsGDTC earnings calendar
▸ Source: FMP · CytoMed Therapeutics Limited SEC filings · US GAAP · CytoMed Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026